Search results for: Market Access
Filter search results
What are the Economic Implications of Moving Away from Paying a Single Price for a Single Drug?
9 July 2018
…assumptions as to where (single) prices are currently set, and the extent to which IBP could expand patient access by allowing further indications to be developed. In our new…
OHE Welcomes Patrick Holmes to the Board of Trustees
28 March 2022
…access to medicines, while allowing the company to continue to develop and deliver innovative treatments. Issue areas include market-based R&D incentives, value and innovation frameworks and sustainable patient-centric health systems….
Does Government Funding Increase Public Sector Development of New Medicines?
5 March 2021
…The Pharmaceutical Industry and Global Health: Facts and Figures 2017. (downloaded from https://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf) Barrenho, E. and Miraldo, M., 2018. R&D Success in Pharmaceutical Markets: A Duration Model Approach. In: Health…
H.R. 3 is the Wrong Policy for the Wrong Problem
10 September 2021
…US life expectancy lags substantially behind that of other developed nations. While this may be partly explained by poor access to health insurance and inequality in access, even those with…
The Digitalisation of Health Care During COVID-19: Consideration of the Long-Term Consequences
28 April 2020
…towards digitalisation of health care allows for potential improvements in access, its impact on health outcomes and health inequalities must be carefully considered to ensure they contribute to social welfare…
Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?
17 September 2020
…at: https://ideas.repec.org/p/chy/respap/54cherp.html [Accessed 14 Oct. 2019]. ISPOR, 2020. Pharmacoeconomic Guidelines Around The World. [online] Available at: https://tools.ispor.org/peguidelines/COMP3.asp [Accessed 3 Sep. 2020]. Jit, M., Hutubessy, R., Png, M.E., Sundaram, N., Audimulam,…
Part 1: 2010 Lecture on US Health Reform
20 July 2010
…charity care; nonprofits and state or local governments provide free clinics, and other means of access of are available. However, access for the uninsured often is not timely or consistent…
Data Governance Arrangements for Real-world Evidence in Japan
12 September 2019
A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how real-world data is accessed…
Future UK Medicines Spending: Four Nation Analysis
31 October 2012
…and generics) were divided into primary care and secondary care markets. 2. For each market, we calculated sales for each of the four nations for 2011. 3. To project sales…